Clinical Trials Logo

Lymphoma, Large B-Cell, Diffuse clinical trials

View clinical trials related to Lymphoma, Large B-Cell, Diffuse.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT04705454 No longer available - Clinical trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)

Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Start date: n/a
Phase:
Study type: Expanded Access

The EAP is for patients with relapsed/refractory diffuse large b-cell lymphoma (R/R DLBCL) that cannot be treated by currently available drugs, cell therapy, or clinical trials. ADC Therapeutics will evaluate patients for approval into the program.